Homology Medicines, Inc. (NASDAQ:FIXX) went up by 3.57% from its latest closing price when compared to the 1-year high value of $24.00 and move down -117.98%, while FIXX stocks collected -1.02% of loss with the last five trading sessions. Press Release reported on 08/10/20 that Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update
Homology Medicines, Inc. (NASDAQ:FIXX) Worth an Investment?
Homology Medicines, Inc. (NASDAQ:FIXX) 9 of the analysts out of 10 who provided ratings for Homology Medicines, Inc. stocks as a “buy” while 1 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $30.22 which is -$11.01 below current price. FIXX currently has a short float of 12.92% and public float of 42.77M with average trading volume of 489.82K shares.
FIXX Market Performance
FIXX stocks went down by -1.02% for the week, with the monthly drop of -19.16% and a quarterly performance of -33.27%, while its annual performance rate touched -43.79%. The simple moving average for the period of the last 20 days is -3.76% for FIXX stocks with the simple moving average of -29.98% for the last 200 days.
Analysts’ Opinion on Homology Medicines, Inc. (NASDAQ:FIXX)
Many brokerage firms have already submitted their reports for FIXX stocks, with H.C. Wainwright repeating the rating for FIXX shares by setting it to “Buy”. The predicted price for FIXX socks in the upcoming period according to H.C. Wainwright is $30 based on the research report published on August 11, 2020.
BofA/Merrill, on the other hand, stated in their research note that they expect to see FIXX stock at the price of $30. The rating they have provided for FIXX stocks is “Buy” according to the report published on June 25, 2020.
RBC Capital Mkts gave “Outperform” rating to FIXX stocks, setting the target price at $30 in the report published on May 13, 2020.
FIXX Stocks -19.41% Far from 50 Day Moving Average
After a stumble in the market that brought FIXX to its low price for the period of the last 52 weeks, Homology Medicines, Inc. was unable to take a rebound, for now settling with -54.12% of loss for the given period.
The stock volatility was left at 5.66%, however, within the period of a single month, the volatility rate increased by 3.42%, while the shares sank at the distance of -18.83% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -28.26% lower at the present time.
In the course of the last 5 trading sessions, FIXX remain unchanged, which changed the moving average for the period of 200 days to the total of -16.58% of losses for the stock in comparison to the 20-day moving average settled at $11.31. In addition, Homology Medicines, Inc. saw -48.65% in overturn over the period of a single year with a tendency to cut further losses.
FIXX Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Homology Medicines, Inc. (FIXX), starting from Kelly Timothy P, who sold 1,315 shares at the price of $13.01 back on Mar 17. After this action, Rushing now owns 0 shares of Homology Medicines, Inc., valued at $17,109 with the latest closing price.
Smith W Bradford, the CFO, Treasurer & Secretary of Homology Medicines, Inc., sold 12,000 shares at the value of $16.16 during a trade that took place back on Feb 03, which means that Smith W Bradford is holding 0 shares at the value of $193,866 based on the most recent closing price.
FIXX Stock Fundamentals
The current profitability levels are settled at -6599.22 for the present operating margin. The net margin for Homology Medicines, Inc. stands at -6237.45. Total capital return value is set at -48.52, while invested capital returns managed to touch -45.86. Equity return holds the value -53.10%, with -42.40% for asset returns.